Rockefeller Capital Management L.P. bought a new stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 8,117 shares of the company’s stock, valued at approximately $690,000.
A number of other hedge funds have also added to or reduced their stakes in HSIC. Mission Wealth Management LP raised its holdings in Henry Schein by 26.9% during the 3rd quarter. Mission Wealth Management LP now owns 4,147 shares of the company’s stock worth $353,000 after buying an additional 878 shares during the period. Boston Family Office LLC acquired a new stake in Henry Schein during the 3rd quarter worth about $214,000. Victory Capital Management Inc. raised its holdings in Henry Schein by 1,912.5% during the 3rd quarter. Victory Capital Management Inc. now owns 46,770 shares of the company’s stock worth $3,977,000 after buying an additional 44,446 shares during the period. Robeco Institutional Asset Management B.V. increased its holdings in shares of Henry Schein by 18.0% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 57,893 shares of the company’s stock valued at $4,923,000 after purchasing an additional 8,827 shares during the period. Finally, Price Capital Management Inc. increased its holdings in shares of Henry Schein by 83.5% in the 3rd quarter. Price Capital Management Inc. now owns 17,471 shares of the company’s stock valued at $1,486,000 after purchasing an additional 7,951 shares during the period.
HSIC has been the topic of a number of research reports. Morgan Stanley upped their target price on Henry Schein from $65.00 to $66.00 and gave the company an “underweight” rating in a report on Tuesday, October 9th. Goldman Sachs Group reiterated a “neutral” rating on shares of Henry Schein in a report on Friday, October 19th. ValuEngine upgraded Henry Schein from a “strong sell” rating to a “sell” rating in a report on Thursday, September 13th. Zacks Investment Research downgraded Henry Schein from a “buy” rating to a “hold” rating in a report on Thursday, August 2nd. Finally, Leerink Swann set a $100.00 target price on Henry Schein and gave the company a “buy” rating in a report on Tuesday, August 7th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $84.18.
Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, November 6th. The company reported $1.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.01 by $0.02. The business had revenue of $3.28 billion during the quarter, compared to analysts’ expectations of $3.37 billion. Henry Schein had a return on equity of 20.40% and a net margin of 3.00%. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.87 EPS. As a group, equities analysts forecast that Henry Schein, Inc. will post 4.11 earnings per share for the current year.
Henry Schein Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Read More: Why do companies issue stock splits?
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.